Latest Oncology News

Ivosidenib/Azacitidine Significantly Improves EFS in Previously Untreated IDH1-Mutated AML

Ivosidenib/Azacitidine Significantly Improves EFS in Previously Untreated IDH1-Mutated AML

August 2nd 2021

Kristi Rosa

The combination of ivosidenib plus azacitidine significantly improved event-free survival compared with azacitidine plus placebo in previously untreated patients with IDH1-mutated acute myeloid leukemia, meeting the primary end point of the phase 3 AGILE trial.

Sotorasib Flips the Switch for Patients With KRAS G12C-Mutant NSCLC

Sotorasib Flips the Switch for Patients With KRAS G12C-Mutant NSCLC

August 2nd 2021

Jackie Collins

Ferdinandos Skoulidis, MD, PhD, discusses the necessity for targeting and screening patients for KRAS G12C mutations.

African Ancestry Is Linked With Higher Prostate Cancer Risk Vs European Ancestry

African Ancestry Is Linked With Higher Prostate Cancer Risk Vs European Ancestry

August 2nd 2021

Hayley Virgil

Germline variation could play a role in racial disparities related to prostate cancer risk, with individuals of African descent having a higher mean genetic risk score compared with men of European ancestry.

Research Efforts Seek to Unlock the Potential of PARP Inhibition in Thoracic Malignancies

Research Efforts Seek to Unlock the Potential of PARP Inhibition in Thoracic Malignancies

August 1st 2021

Courtney Marabella

Ongoing studies with biomarker-selected cohorts may help to identify subsets of patients with thoracic malignancies who might confer benefit from PARP inhibitors.

Utility of Immunotherapy Keeps Evolving in Unresectable Stage III NSCLC

Utility of Immunotherapy Keeps Evolving in Unresectable Stage III NSCLC

July 31st 2021

Hayley Virgil

Many checkpoint inhibitors are currently under investigation in combination with concurrent radiotherapy in stage III non–small cell lung cancer, which experts propose could have practice-changing implications.

Latest Oncology Videos

All Oncology News

NSCLC: Sotorasib in Practice

July 29th 2021

Ben Levy, MD, The Johns Hopkins University School of Medicine

Experts share their real-world experiences regarding treatment with sotorasib, a new FDA-approved option for KRAS G12C-mutated non–small cell lung cancer (NSCLC).

Recent FDA-Approvals: KRAS G12C-Mutated NSCLC

July 29th 2021

Ben Levy, MD, The Johns Hopkins University School of Medicine

An overview of new data presented at the American Society of Clinical Oncology 2021 annual meeting for KRAS G12C-mutated non–small cell lung cancer (NSCLC).

Dr. Liao on Outcomes With Ivosidenib in Advanced Cholangiocarcinoma

July 28th 2021

Chih-Yi Liao, MD

Chih-Yi Liao, MD, discusses outcomes reported with ivosidenib in patients with advanced cholangiocarcinoma.

Dr. Rosenberg on Adapting Treatment Decisions Based on MRD in Multiple Myeloma

July 28th 2021

Aaron Seth Rosenberg, MD, MS

Aaron Seth Rosenberg, MD, MS, discusses the emerging role of minimal residual disease to guide treatment decisions in multiple myeloma.

Dr. Basho on the Evolution of Therapeutic Sequencing in HER2+ Breast Cancer

July 28th 2021

Reva K. Basho, MD

Reva K. Basho, MD, discusses the evolution of therapeutic sequencing in HER2-positive breast cancer.

KAMILLA Data Reinforce Favorable Benefit/Risk Profile of T-DM1 in HER2+ Breast Cancer

July 28th 2021

Ryan Scott

Rachel Wuerstlein, MD, discusses the safety and the efficacy observed with ado-trastuzumab emtansine in patients with HER2-positive breast cancer and the next steps for research with the agent.

With Novel Combos on the Horizon, End Points Beyond OS May Hold Promise in HR-MDS

July 28th 2021

Jessica Hergert

Novel combinations with agents, such as pevonedistat, eprenetapopt, venetoclax or magrolimab, plus hypomethylating agents like azacitidine are being evaluated to determine whether they can improve upon the lackluster median survival for patients with higher-risk myelodysplastic syndrome.

Dr. Morris Discusses Ongoing Research With 177Lu-PSMA-617 in Prostate Cancer

July 28th 2021

Michael J. Morris, MD

Michael J. Morris, MD, discusses ongoing research efforts with 177Lu-PSMA-617 in prostate cancer.

Dr. Monk on the Utility of PARP Inhibitors as Maintenance Therapy in Ovarian Cancer

July 28th 2021

Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology

Bradley J. Monk, MD, FACS, FACOG, discusses the utility of PARP inhibitors as maintenance therapy in ovarian cancer.

Dr. Dreicer on the Clinical Implications of the JAVELIN Bladder 100 Trial in Urothelial Cancer

July 28th 2021

Robert Dreicer, MD

Robert Dreicer, MD, discusses the clinical implications of the phase 3 JAVELIN Bladder 100 trial in locally advanced or metastatic urothelial cancer.

High Visceral Fat Index Associated With Worse Survival Outcomes in Early-Stage Lung Cancer

July 28th 2021

Hayley Virgil

The method used to calculate how obesity is measured may impact whether it should be considered as a risk factor for non–small cell lung cancer.

Triplet Combination Demonstrates Promise for Frontline Treatment of BRAF V600E–mutant CRC

July 28th 2021

Brittany Lovely

Doublet and triplet chemotherapy-based therapies are standard treatment options for patients with BRAF V600–mutant metastatic colorectal cancer.

Challenges Arise as Public Health and Scientific Communication Enters Uncharted Territory

July 28th 2021

Maurie Markman

It is difficult to dispute that these are troubling times for government officials and public health agencies.

Joseph W. Kim Receives Prestigious 2021 Cancer Clinical Investigator Team Leadership Award

July 28th 2021

Joseph W. Kim, MD, Associate Professor of Medicine at Yale Cancer Center, has received a 2021 Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute.

New Tool Improves Accurate Excision of Previously Positive Axillary Lymph Nodes After Neoadjuvant Chemo in Breast Cancer

July 28th 2021

Courtney Marabella

Leslie L. Montgomery, MD, and Tara M. Balija, MD, discuss the benefits of a novel reflector device in patients with breast cancer, its efficacy in identifying clipped axillary lymph nodes, and the potential future use of this device in other cancer types.

See All News